Interim clinical results on the treatment of HPV induced neoplasia and carcinoma with a live attenuated Listeria immunotherapy

In R&D by Freya SmaleLeave a Comment

download, HPV

Dr John Rothman, Executive Vice President Science & Operations, Advaxis, joined us at the World Vaccine Congress Lyon 2012 to give details on the interim clinical results on the treatment of HPV induced neoplasia and carcinoma with a live attenuated Listeria immunotherapy.

Here is a taster of what you can discover from this presentation:
Listeria monocytogenes (Lm) based Lm-LLO Immunotherapies

•A simple concept: We are using a persistent, protective immune response to an attenuated bacteria; only our bacteria secretes tumor or other disease antigens.

-Live metabolically competent Listeria is more complex than antibodies or synthetic molecules and engenders a more compete immune response

•We are born with an immune response to Lm

-Pathogen Associated Molecular Patterns (PAMP)

-Non-pathogenic: attenuated 104 -105 times

-Secrete an antigen fused to a non-hemolytic, highly immunogenic truncated fragment of LLO

•Adds to native LLO, P60, Plc A & B, Flagellin, etc.

Interim clinical results on the treatment of HPV induced neoplasia and carcinoma with a live attenuated Listeria immunotherapy

· ADXS11-001 is currently in 5 phase 2 trials for the treatment of cervix cancer, head and neck cancer, anal cancer, and cervical dysplasia

· The agent has been well tolerated and has generated a strong efficacy signal

· Preliminary results observed thus far and future directions will be presented

Dr John Rothman, Executive Vice President Science & Operations, Advaxis

Download the presentation here >

To learn more about this and the other topics discussed at this event, please click here >

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *